Kymera Therapeutics (KYMR) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
47.1M
Operating Income
-256.7M
-545.36%
Net Income
-223.9M
-475.57%
Balance Sheet Metrics
Total Assets
978.0M
Total Liabilities
142.4M
Shareholders Equity
835.6M
Debt to Equity
0.17
Cash Flow Metrics
Operating Cash Flow
-180.7M
Free Cash Flow
-207.3M
Revenue & Profitability Trend
Kymera Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 47.1M | 78.6M | 46.8M | 72.8M | 34.0M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 303.8M | 244.1M | 208.1M | 173.4M | 80.3M |
| Operating Income | -256.7M | -165.5M | -161.3M | -100.5M | -46.3M |
| Pre-tax Income | -223.9M | -147.0M | -154.8M | -100.2M | -45.6M |
| Income Tax | - | - | - | - | - |
| Net Income | -223.9M | -147.0M | -154.8M | -100.2M | -45.6M |
| EPS (Diluted) | - | -$2.52 | -$2.87 | -$2.09 | -$3.15 |
Income Statement Trend
Kymera Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 510.3M | 405.3M | 419.4M | 451.3M | 302.3M |
| Non-Current Assets | 467.8M | 170.4M | 183.7M | 154.6M | 184.8M |
| Total Assets | 978.0M | 575.8M | 603.1M | 605.9M | 487.2M |
| Liabilities | |||||
| Current Liabilities | 67.8M | 85.7M | 71.3M | 92.5M | 110.6M |
| Non-Current Liabilities | 74.6M | 95.1M | 41.6M | 53.7M | 92.7M |
| Total Liabilities | 142.4M | 180.8M | 113.0M | 146.3M | 203.3M |
| Equity | |||||
| Total Shareholders Equity | 835.6M | 395.0M | 490.2M | 459.6M | 283.9M |
Balance Sheet Composition
Kymera Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -223.9M | -147.0M | -154.8M | -100.2M | -45.6M |
| Operating Cash Flow | -180.7M | -98.8M | -157.5M | -143.4M | 84.6M |
| Investing Activities | |||||
| Capital Expenditures | -12.8M | -34.5M | -2.8M | -1.6M | -9.1M |
| Investing Cash Flow | -404.1M | 139.9M | 20.5M | -99.8M | -422.6M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 595.0M | -76.0K | 148.7M | 241.9M | 289.1M |
| Free Cash Flow | -207.3M | -137.3M | -155.9M | -130.5M | 79.0M |
Cash Flow Trend
Kymera Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-14.88
Price to Book
3.83
Price to Sales
51.19
PEG Ratio
-14.88
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-336.77%
Return on Equity
-32.17%
Return on Assets
-19.47%
Financial Health
Current Ratio
8.49
Debt to Equity
10.98
Beta
2.07
Per Share Data
EPS (TTM)
-$3.11
Book Value per Share
$12.08
Revenue per Share
$0.76
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| kymr | 3.0B | - | 3.83 | -32.17% | 0.00% | 10.98 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.